Data have been presented in part at the 2012 Annual Meeting of the American Society of Hematology; December 8-11, 2012; Atlanta, GA.
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
Article first published online: 30 OCT 2013
© 2013 The Authors published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Volume 120, Issue 4, pages 513–520, 15 February 2014
How to Cite
Verstovsek, S., Passamonti, F., Rambaldi, A., Barosi, G., Rosen, P. J., Rumi, E., Gattoni, E., Pieri, L., Guglielmelli, P., Elena, C., He, S., Contel, N., Mookerjee, B., Sandor, V., Cazzola, M., Kantarjian, H. M., Barbui, T. and Vannucchi, A. M. (2014), A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer, 120: 513–520. doi: 10.1002/cncr.28441
We thank Kris Vaddi, PhD, for biomarker data review; Kevin Hou, PhD, for biostatistical support; William Garrett, MBA, for study management; and Hema Gowda, PharmD, for medical writing assistance (all from Incyte Corporation). Granulocyte activation studies were performed at the Fondazione IRCCS Policlinico San Matteo and the University of Pavia in Pavia, Italy. Studies of microRNA expression were conducted at the Section of Hematology at the University of Florence in Florence, Italy, with the acknowledged contribution of Rossella Manfredini of the University of Modena and Reggio Emilia in Modena, Italy.
- Issue published online: 4 FEB 2014
- Article first published online: 30 OCT 2013
- Manuscript Accepted: 17 SEP 2013
- Manuscript Revised: 4 SEP 2013
- Manuscript Received: 21 AUG 2013
- 15A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148:961-963., , , et al.
- 18National Cancer Institute Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed August 15, 2013.
- 22Complete hematological, molecular and histological remissions without cytoreductive treatment lasting after pegylated-interferon α-2a (peg-IFNα-2a) therapy in polycythemia vera (PV): long term results of a phase 2 trial [abstract]. Presented in abstract form at: American Society of Hematology Annual Meeting and Exposition; December 10-12, 2011; San Diego, CA. Abstract 280..
- 30Efficacy, safety, and survival with ruxolitinib treatment in patients with myelofibrosis results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013 Sept 13. Epub ahead of print. PMID 24038026., , , et al.
- 31Long-term safety, efficacy, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Presented in abstract form at: American Society of Hematology Annual Meeting and Exposition; December 8-11, 2012; Atlanta, GA. Abstract 801., , , et al.